<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Flip News — lung-cancer news</title>
    <link>https://flipnews.co.uk/topics/lung-cancer/</link>
    <description>The latest Flip News stories on lung-cancer.</description>
    <language>en-GB</language>
    <lastBuildDate>Tue, 06 Oct 2026 18:01:02 GMT</lastBuildDate>
    <atom:link href="https://flipnews.co.uk/topics/lung-cancer/feed.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>ArriVent's lung cancer drug fails late-stage FURVENT trial; shares halted</title>
      <link>https://flipnews.co.uk/health/arrivent-furvent-phase3-failure/</link>
      <guid isPermaLink="true">https://flipnews.co.uk/health/arrivent-furvent-phase3-failure/</guid>
      <pubDate>Tue, 06 Oct 2026 00:00:00 GMT</pubDate>
      <description>ArriVent BioPharma said its lung cancer therapy firmonertinib failed to meet the main goal of the pivotal Phase 3 FURVENT trial, and its shares were halted in premarket trading.</description>
      <author>Priya Raman</author>
      <category>arrivent</category>
      <category>firmonertinib</category>
      <category>lung-cancer</category>
      <category>clinical-trial</category>
      <source url="https://www.reuters.com/business/healthcare-pharmaceuticals/arrivents-lung-cancer-treatment-fails-late-stage-trial-2026-10-06/">Reuters</source>
    </item>
  </channel>
</rss>
